A Case of COVID-19-Associated Autoimmune Hemolytic Anemia With Hyperferritinemia in an Immunocompetent Host

Zoha Huda 1, Abdallah Jahangir 2, Syeda Sahra 3, Muhammad Rafay Khan Niazi 3, Shamsuddin Anwar 2, Allison Glaser 4, Ahmad Jahangir 5

1. Medicine, The City University of New York (CUNY) School of Medicine, New York, USA 2. Internal Medicine, Staten Island University Hospital, Northwell Health, New York, USA 3. Internal Medicine, Northwell Health, New York, USA 4. Infectious Disease, Northwell Health, New York, USA 5. Internal Medicine, Mayo Hospital, Lahore, PAK

Corresponding author: Syeda Sahra, syrabukhari@gmail.com

Abstract
We report an interesting case of a middle-aged gentleman who presented with diabetic ketoacidosis (DKA) and tested polymerase chain reaction (PCR) positive for COVID-19 infection. His hospital stay was complicated by acute kidney injury, hematuria, and normocytic anemia. Initial chest x-ray demonstrated bibasilar opacities. D-dimer and C-reactive protein were elevated. During his hospital stay, his hemoglobin decreased from 13.4 g/dL to 9 g/dL, and further workup demonstrated ferritin of 49,081 ng/mL with lactate dehydrogenase of 1665 U/L. He was treated with prednisone and folic acid for autoimmune hemolytic anemia (AIHA). Ferritin was downtrended, and hemoglobin stabilized. As demonstrated by this case report and prior literature review, COVID-19 infection can be associated with AIHA.

Introduction
Information regarding COVID-19 and associated coagulopathies is rapidly evolving and expanding. Thus far, many cases of autoimmune hemolytic anemia (AIHA) have been reported in patients with comorbidities such as thrombocytopenia, leukemia, lymphoma, various cancers, and autoimmune conditions [1]. The prevalence and significance of AIHA in COVID-19 patients warrant further exploration to elucidate treatment and clinical outlook. We report a case of AIHA and an extremely elevated ferritin level associated with COVID-19 in a patient with no other major risk factors for hemolysis. To our knowledge, this is one of the rare cases of a patient with no underlying malignancy or hematologic dyscrasia presenting with AIHA and COVID-19, and the highest ferritin was reported in this context. This case further supports AIHA as another complication of COVID-19. Additionally, this highlights the importance of laboratory data such as hemoglobin, D-dimer, lactate dehydrogenase (LDH), and ferritin as markers of prognosis and severity of COVID-19 infection [2].

Case Presentation
A 54-year-old male with a history of uncontrolled diabetes mellitus presented to the emergency room complaining of dyspnea with nausea, vomiting, and polyuria in the preceding days. His COVID-19 rapid testing was positive. The patient was vitally stable and not hypoxemic, thus did not meet the criteria for COVID-19 therapeutics. On admission, glucose was 373 mg/dL, anion gap was 28, carbon dioxide was 7 mEq/L, and b-hydroxybutyrate was > 9 mmol/L. VBG showed partial pressure of carbon dioxide (PCO2) of 22 mmHg and bicarbonate of 8 mEq/L. Chest x-ray showed diffuse bilateral opacities (Figure 1).
He was subsequently admitted for diabetic ketoacidosis, and his hospital stay was complicated by acute kidney injury, hematuria, and AIHA.

On day 8 of hospital admission, microhematuria was noted with urinalysis demonstrating 28 red blood cells per high power field (RBC/HPF). Hemoglobin levels declined from 13.4 g/dL on presentation to 9.0 g/dL while C-reactive protein (CRP) increased to 3.7 mg/L from 0.44 mg/L. D-dimer trended from 226 to 373 ng/mL. The renal sonogram was negative for stones and hydronephrosis. Initial ferritin increased from 3,343 to 49,081 ng/mL on day 6, and further workup demonstrated a positive direct Coombs for IgG on day 9, reticulocyte count of 1.9% with an absolute reticulocyte count of 53.6 K/uL, total bilirubin of 1.4 mg/dL, creatine kinase of 248 U/L, ESR of 90 mm/hr, haptoglobin of 30 mg/dL, and LDH of 1665 U/L (Table 1).
### Hematology

| Hematology                  | Day 1  | Day 2  | Day 3  | Day 4  | Day 5  | Day 6  | Day 7  | Day 8  | Day 9  | Day 10 | Day 11 | Day 12 |
|-----------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Hemoglobin (13.5-17.5 g/dL) | 13.4   | 12.3   | 11.4   | 11.6   | 12     | 11.9   | 11.2   | 9.9    | 9.4    | 9.0    | 9.1    | 8.1    |
| WBC (4-11 K/μL)             | 9.95   | 7.83   | 5.27   | 3.77   | 4.85   | 6.26   | 7.91   | 9.92   | 10.45  | 9.77   | 10.33  | 16.1   |
| Platelets (150-450 K/μL)   | 206    | 165    | 188    | 168    | 148    | 177    | 210    | 274    | 291    | 365    | 457    | 541    |
| CRP (<10 mg/L)              | 0.44   | 0.71   | 3.06   | 3.70   |        |        |        |        |        |        |        |        |
| Haptoglobin (41-165 mg/dL)  |        |        |        |        |        | 41     | 30     |        |        |        |        |        |
| Procalcitonin (<0.15 ng/mL) | 0.11   | 0.09   | 0.13   | 0.15   | 0.15   |        |        |        |        |        |        |        |
| Ferritin (24-336 ng/mL)     | 3343   |        |        |        |        | 49,081 (repeated) | 27,109 (repeated) |        |        |        |        |        |
| LDH (140-280 u/L)           | 172    |        |        |        |        | 1780   | 1665   |        |        |        |        |        |
| D-dimer (<0.5 mg/mL)        | 226    | 293    | 3661   |        |        |        |        |        |        |        |        |        |
| Bilirubin (total) (1-1.2 mg/dL) | 0.7   | 1     | 1.2    |        |        | 1.6    | 1.4    | 1.3    | 1      |        |        |        |
| AST (5-40 u/L)              | 28     | 24     | 25     |        |        |        | 254    | 143    | 98     |        |        |        |
| ALT (7-56 u/L)              | 28     | 25     | 22     |        |        |        | 79     | 57     | 54     |        |        |        |
| Reticulocyte count (0.5%-1.5%) |        |        |        |        |        |        | 1.5    |        |        |        |        | 1.9    |

### TABLE 1: Hematology panel and inflammatory markers throughout hospitalization (reference ranges added for the average adult male)

WBC, White blood cells; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine transaminase; LDH, lactate dehydrogenase.

Vitamin B12, folate, and ultrasound of the spleen and liver were normal. The patient was negative for hepatitis A/B/C, HIV, and cytomegalovirus antibodies. Immune-mediated hemolysis was suspected due to anemia, direct Coombs positivity, low haptoglobin, and elevated LDH. Prednisone 80 mg and 1 mg of folic acid were started on day 7 of hospitalization (weight-based). Ferritin trended down to 27,109 and hemoglobin stabilized. Hyperferritinemia was attributed to diabetic ketoacidosis, COVID-19, and acute kidney injury. There was no suspicion of hemophagocytic lymphohistiocytosis. The patient was discharged home with no complications.

### Discussion

AIHA can be idiopathic or secondary to other autoimmune disorders, malignancies, and infections [3]. Some studies have demonstrated AIHA in COVID-19-positive patients with underlying malignancies or autoimmune disorders [4-12]. However, autoimmune complications because of COVID-19 in patients without associated comorbidities remain to be elucidated. Few studies have noted that AIHA develops in COVID-19-positive patients with no autoimmune disorder or malignancy history. One case of COVID-19 and unprovoked methemoglobinemia has been reported recently [13].

AIHA is an acquired rare condition that develops when autoantibodies develop against self-antigens on the RBCs, which leads to their destruction by the reticuloendothelial system or complement-mediated cell destruction. Cytomegalovirus, Epstein-Barr virus, Coxsackie virus, Parvovirus B19, Hepatitis C virus, mycoplasma, and several concurrent lymphoproliferative disorders can provoke AIHA. The exact mechanism behind this viral-induced cell destruction is unknown, but in most of the literature, it is attributed to molecular mimicry, which leads to self-reactive lymphocytes and unresponsiveness to self-antigens [14,15]. Therefore, after excluding lymphoproliferative disorders, we can proclaim virus-induced AIHA as a cause behind anemia in our case.

Some common laboratory findings in AIHA include anemia, which can be subtle in mild hemolysis. Platelet count and white blood cell count are usually within normal limits; counts can be depressed in some cases of...
bone marrow suppression from viral infection. Peripheral smear is remarkable for red cell agglutination and spherocytosis. Reticulocyte count and index are increased as a normal bone marrow response to hemolysis. Sometimes reticulocytosis is not evident due to bone marrow disorder or suppression from sepsis. Haptoglobin is decreased, and LDH is elevated; however, LDH may also be elevated as an inflammatory marker from sepsis in COVID-19 infection with lung involvement. This overlap can make it difficult to discern the cause. Urinalysis is positive for blood but negative for erythrocytes. The positive direct antiglobulin test (DAT) represents attachment of complement C3D and immunoglobulins IgG, IgM, IgA to erythrocyte membrane [16]. Ferritin itself is an inflammatory marker, and a previous study shows that in patients with AIHA, a highly significant difference is present in the ferritin levels among patients with hemolysis compared to those in remission [17].

Further investigation regarding the possibility that COVID-19 may cause AIHAs is needed. Of documented cases, AIHA manifested around a median of eight to nine days [18]. Labs may show increased reticulocyte count, LDH, decreased haptoglobin, and indirect bilirubinemia. Complete blood count, D-dimer, coagulation studies, CRP, and ferritin are also important to monitor in patients with COVID-19 [10]. This case demonstrates the highest recorded ferritin level in the context of a COVID-19-positive patient with anemia thus far. In particular, elevated D-dimer, LDH, ferritin, and decreased hemoglobin have correlated to a poorer prognosis of COVID-19 [19]. Anemia was initially presumed to be due to acute illness, specifically dilutional anemia secondary to diabetic ketoacidosis. Therefore, it is important to recognize AIHA as a potential sequela of COVID-19 and to monitor positive patients in the future to hasten treatment and predict the clinical course potentially. A systematic review by Taherifard et al. (2021) highlighted the association of COVID-19 with autoimmune anemias with stress on testing for COVID-19 in sudden anemias in appropriate clinical settings [19].

In terms of treatment, glucocorticoids remain the first-line treatment for AIHA in these patients. Treatment should be initiated with the dose of 1 mg/kg/day prednisone orally or methylprednisolone intravenously [20]. This initial dose is continued until hemoglobin is increased to 10 mg/dl or by 30% of the initial value. If this goal is not achieved after the treatment with steroids within three weeks, other treatment options are considered because there are higher chances of treatment failure. Rituximab and splenectomy are the only second-line treatments with proven efficacy [21]. There are case reports of the use of rituximab in COVID-19, but the decision is complex since rituximab suppresses humoral immunity, which leads to an inability to develop antibodies against the COVID-19 virus [22].

**Conclusions**

The association between AIHA and COVID-19 remains to be elucidated. In many cases, AIHA occurred in COVID-19-positive patients with a history of malignancies or autoimmune comorbidities. However, more research is required to examine the link between COVID-19 and AIHA in patients with minimal or no comorbidities.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Saad MA, Alfishawy M, Nassar M, Mohamed M, Esene IN, Elbendary A: COVID-19 and autoimmune diseases: a systematic review of reported cases. Curr Rheumatol Rev. 2021, 17:193-204. 10.2174/1573397116666201029155856
2. Algassim AA, Elghazaly AA, Alnahdi AS, et al.: Prognostic significance of haptoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Annals of hematology. 2020, 100:57-65. 10.1007/s00277-020-00140-y
3. Liebman HA, Weitz IC: Autoimmune hemolytic anemia. Med Clin North Am. 2017, 101:351-9. 10.1016/j.mcna.2016.09.007
4. Zagorski E, Pawar T, Rahimian S, Forman D: Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19). Br J Haematol. 2020, 190:e185-4. 10.1111/bjh.16892
5. Nesr G, Koshy R, Foldes D, Kagdi H: Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naive chronic lymphocytic leukaemia: a case report. Br J Haematol. 2020, 190:e226-8. 10.1111/bjh.17079
6. Lopez C, Kim J, Pandey A, Huang T, DeLoughery TG: Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia. Br J Haematol. 2020, 190:51-2. 10.1111/bjh.16786
7. Lazarian G, Quinquean E, Bellal M, et al.: Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol. 2020, 190:29-31. 10.1111/bjh.16794
8. Capes A, Bailly S, Hantson P, Gerard L: Laterre P-F. COVID-19 infection associated with autoimmune
hemolytic anemia. Annals of hematology. 2020, 99:1679-80. 10.1007/s00277-020-04137-9
9. Murtas R, Andreano A, Gervasi F, et al.: Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case-control and population case-control design. Auto Immun Highlights. 2020, 11:15. 10.1186/s13757-020-00141-1
10. Patil NR, Here ES, Girgis M: Cold agglutinin disease and autoimmune hemolytic anemia with pulmonary embolism as a presentation of COVID-19 infection [IN PRESS]. Hematol Oncol Stem Cell Ther. 2020, 10.1016/j.hemonc.2020.06.005
11. Phillips L, Pavsic J, Kaur D, Dorrello NV, Broglie L, Hijiiya N: Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2020, 4:4358-61. 10.1182/bloodadvances.2020002745
12. Wahlster I, Weichert-Leahey N, Trissal M, Grace RF, Sankaran VG: COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. Pediatr Blood Cancer. 2020, 67:e28382. 10.1002/pbc.28382
13. Lopes DV, Neto FL, Marques LC, Lima RBO, Brandão AAGS: M ethemoglobinemia and hemolytic anemia after COVID-19 infection without identifiable eliciting drug: a case-report. iDCases. 2021, 25:01013-10. 10.1016/j.idcr.2020.e01013
14. von Herrath MG, Oldstone MB: Virus-induced autoimmune disease. Curr Opin Immunol. 1996, 8:878-85. 10.1016/s0952-7915(96)80019-7
15. Meite M, Léonard S, Idrissi ME, Izuí S, Masson PI, Couteilier JP: Exacerbation of autoantibody-mediated hemolytic anaemia by viral infection. J Virol. 2000, 74:6045-9. 10.1128/jvi.74.13.6045-6049.2000
16. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A: The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017, 176:595-411. 10.1111/bjh.14478
17. Brabec V, Cermák J, Sebestík V: Serum ferritin in patients with various haemolytic disorders. Folia Haematol Int Mag Klin Morphol Blutforsch. 1990, 117:219-27.
18. Pelle MC, Tassone B, Ricchio M, et al.: Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report. J Med Case Rep. 2020, 14:246. 10.1186/s13256-020-02595-5
19. Taherifard E, Taherifard E, Movahed H, Mousavi MR: Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. Hematology. 2021, 26:225-39. 10.1080/16078454.2021.1891225
20. Murphy S, LoBuglio AF: Drug therapy of autoimmune hemolytic anemia. Semin Hematol. 1976, 13:325-34.
21. Lechner K, Jäger U: How I treat autoimmune hemolytic anemias in adults. Blood. 2010, 116:1831-8. 10.1182/blood-2010-05-259325
22. Yasuda H, Tsukane Y, Watanabe N, et al.: Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2020, 20:774-6. 10.1016/j.clml.2020.08.017